SHIELD: Sorafenib Hand-foot Syndrome Inhibition With Pre-Emptive Local Delivery of Topical Indomethacin | MicrobiomeTrials← Back to trialsNCT07560566
SHIELD: Sorafenib Hand-foot Syndrome Inhibition With Pre-Emptive Local Delivery of Topical Indomethacin
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2025-12-09Est. Completion: 2029-04-30
Enrollment target: 39 participants Locations- National Taiwan University Hospital, Taipei, Taiwan
Other microbiome trials you might be interested in
Hepato Cellular Carcinoma
Conventional transarterial chemoembolization with Doxorubicin (c-TACE) is the gold standard treatment for Hepato Cellula…
Strasbourg, FranceCompleted Oct 9, 2019
Hepato Cellular Carcinoma (HCC)
The purpose of this study is to evaluate whether fecal microbiota transplantation (FMT), when administered in combinatio…
Bologna, ItalyEst. completion Jan 1, 2027